EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Extreme bradycardia in BRASH syndrome unmasked by severe amiodarone-induced hypothyroidism

Julien Kasambi Bayanda

European Journal of Case Reports in Internal Medicine · 2026-10-26 · 13 (11)

DOI: 10.12890/2026_007298 ↗
AbstractBibliografische Angaben

Abstract

Introduction: BRASH syndrome – bradycardia, renal failure, AV nodal blockade, shock and hyperkalaemia – is a self-amplifying pathophysiological loop. Its association with severe amiodarone-induced hypothyroidism is rarely described in detail. Case description: A 79-year-old woman with permanent atrial fibrillation on long-term amiodarone and bisoprolol presented after prolonged unwitnessed floor immobilisation with extreme bradycardia (24–30 bpm), haemodynamic instability, KDIGO stage 3 acute kidney injury, hyperkalaemia (5.5 mmol/l), metabolic acidosis, rhabdomyolysis and profound hypothyroidism (TSH 68.5 mUI/l; free T4 4.62 pmol/l) against a normal thyroid baseline 13 months prior. The Popoveniuc myxoedema coma score was 45 (high-risk zone). High-sensitivity troponin T showed flat kinetics consistent with type 2 myocardial injury. Isoproterenol was required for bradycardia refractory to initial metabolic correction, achieving a ventricular rate of 62–68 bpm with QTc shortening from 0.62 s to 0.38 s. The patient was discharged on day 8 with renal recovery and improving thyroid function. Thyroid antibody negativity at 30-day follow-up was consistent with an amiodarone-induced rather than autoimmune aetiology. Conclusion: This case illustrates BRASH syndrome presenting with only mild hyperkalaemia in the context of severe amiodarone-induced hypothyroidism, which may have potentiated the pathophysiological loop. Systematic thyroid monitoring during long-term amiodarone therapy and multi-target metabolic correction, including isoproterenol as a pharmacological bridge, may avert invasive pacing.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →